Medication use in pregnancy and the pregnancy and lactation labeling rule

Clin Pharmacol Ther. 2016 Jul;100(1):23-5. doi: 10.1002/cpt.380. Epub 2016 May 9.

Abstract

On 30 June 2015, the US Food and Drug Administration Pregnancy and Lactation Labeling Rule (PLLR) took effect. This rule sets new and improved standards for the inclusion of information about the use of prescription drugs and biological products during pregnancy and lactation. The new labeling requirements have important implications for clinical pharmacology as there is a subheading that is dedicated to inclusion of clinical pharmacology information that inform dosing during pregnancy and the postpartum period, if available.

MeSH terms

  • Biological Products / administration & dosage
  • Biological Products / adverse effects
  • Biological Products / pharmacology
  • Breast Feeding
  • Drug Labeling / legislation & jurisprudence*
  • Drug Labeling / standards
  • Drug-Related Side Effects and Adverse Reactions / prevention & control
  • Female
  • Humans
  • Lactation*
  • Postpartum Period
  • Pregnancy
  • Prescription Drugs / administration & dosage*
  • Prescription Drugs / adverse effects
  • Prescription Drugs / pharmacology
  • United States
  • United States Food and Drug Administration

Substances

  • Biological Products
  • Prescription Drugs